Abstract 3385: Liquid biopsy to detect <i>MET</i> exon 14 skipping (<i>MET</i>ex14) and <i>MET</i> amplification in patients with advanced NSCLC: Biomarker analysis from VISION study

Xiuning Le(The University of Texas MD Anderson Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), PierFranco Conte(University of Padua), Santiago Viteri(Instituto Oncológico Dr. Rosell), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Byoung Chul Cho(Yonsei University), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Gee‐Chen Chang(National Yang Ming Chiao Tung University), L. Paz-Ares(Hospital Universitario 12 De Octubre), John M. Richart(Saint Louis University), Enriqueta Felip(Institut Català d'Ornitologia), Marina Chiara Garassino(University of Chicago), Josef Straub(Inserm), Christopher Stroh(Universität Hamburg)
Cancer Research
August 15, 2020
10.1158/1538-7445.am2020-3385
Cited by 9

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k